Above the scientific discussions and deal talks at ASCO 2026, the dark cloud of geopolitics hovered over the Chicago convention center. (Angus Liu/Fierce Pharma) In 2017, a little-known company called ...
RASolute 302 showed daraxonrasib reduced mortality risk by 60% versus chemotherapy in previously treated metastatic PDAC, with median OS 13.2 versus 6.7 months. OPTIMA found Prosigna-defined low-risk ...
Three phase III trial results presented at the 2026 American Society of Clinical Oncology annual meeting in Chicago this weekend delivered what oncologists are already calling the most consequential ...
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the phase III RASolute 302 study of its ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Tempus AI (TEM) stock immediately jumped over ~3% to ~$53.15 before pulling back on Friday after unveiling new AI-driven precision medicine data at the 2026 ASCO Annual Meeting. The healthcare ...
Graig Suvannavejh, Managing Director of Equity Research at Mizuho Securities, discusses major ASCO presentations, biotech volatility, cancer breakthroughs and emerging oncology companies to watch. Got ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Pharma brands are increasingly investing in having a big brand presence at ASCO, with marketers and sales reps manning booths, hoping to carve out a place in a highly competitive oncology arena.
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...
Frontline EGFR exon 20, adjuvant RET, and long-term ALK data are expected to sharpen biomarker-driven selection and potentially reset standards in defined molecular NSCLC subsets. PD-1/VEGF bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results